Skip to main content
UniHealth

Doctor search

Ronald M Witteles, MD

Cardiovascular Disease (Cardiology) · Stanford

NPI 1285779389

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
13
2 carriers
Offices
2

Offices

2 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plans that list them

13 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Witteles’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

13 of 13 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A76510 · Current

Licensed to practise in California · since 2001 · expires 2027-04-30 · University of Chicago, Pritzker School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$92,507

Medicare paid this office $92,507 for 402 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)111$17,685$125
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes34$13,112$103
Critical care, first 30-74 minutes22$11,303$179
Return visit (30+ min)120$9,628$77
New patient visit (60+ min)54$8,486$157
See all 16 services
Every Original Medicare service billed
Long return visit (40+ min)111$17,685$125
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes34$13,112$103
Critical care, first 30-74 minutes22$11,303$179
Return visit (30+ min)120$9,628$77
New patient visit (60+ min)54$8,486$157
Long return visit (40+ min)36$7,150$159
Return visit (30+ min)49$5,929$116
Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days57$3,737$29
Critical care, each additional 30 minutes13$2,790$93
Initial hospital care with moderate level of medical decision making at least 75 minutes18$2,564$142
Hospital discharge day management, 30 minutes or less27$2,029$72
Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days25$1,451$23
Programming of multiple lead implantable defibrillator system23$1,428$49
Programming of dual lead implantable defibrillator system15$833$46
Programming of dual lead pacemaker system13$531$31
Programming of multiple lead pacemaker system11$409$37

Who their Medicare patients are

402 Original Medicare patients in 2024. Average age 76 · Under 65 7% · 85 and older 15% · Women 32% · Also on Medicaid 17% · Health risk score 2.31. Above the middle of the specialty; the typical cardiology clinician is at 1.71.

Conditions among them: High blood pressure 75% · Heart failure 75% · Atrial fibrillation 54% · Coronary heart disease 46% · Chronic kidney disease 45% · Diabetes 33% · Cancer 20% · Depression 15% · COPD 14% · Stroke 9% · Dementia 8%.

The office billed $444,122, Medicare allowed $121,225 and paid $92,507; for 1,003 services of 26 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20244021,003762.31$444,122$92,507
20234331,161752.28$573,624$116,645
20224121,298752.42$792,376$137,664
20214101,276742.47$666,043$127,311
20204081,337742.61$673,736$131,171
20194201,183742.54$402,629$110,658
20183781,246732.75$525,124$120,957
20173671,269722.68$605,588$126,839
20163621,199722.60$595,709$123,054
20153181,037722.48$447,138$100,404
20143211,227722.30$486,836$117,392
20133891,128712.14$389,138$92,046

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 14 services

Original Medicare services billed in 2023
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes59$24,683$109
Critical care, first 30-74 minutes38$22,721$191
Long return visit (40+ min)121$21,676$129
Return visit (30+ min)176$15,137$78
New patient visit (60+ min)52$8,526$164
Initial hospital care with moderate level of medical decision making at least 75 minutes36$5,773$156
Hospital discharge day management, 30 minutes or less41$3,163$75
Critical care, each additional 30 minutes15$2,894$96
Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days51$2,595$32
Programming of dual lead implantable defibrillator system32$1,730$48
Programming of multiple lead implantable defibrillator system28$1,708$52
Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days21$937$27
Programming of dual lead pacemaker system17$657$35
Heart rhythm review and interpretation of continous external ekg over 8-15 days18$431$22

2022: 15 services

Original Medicare services billed in 2022
Critical care, first 30-74 minutes42$44,696$196
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes54$19,387$94
Long return visit (40+ min)112$18,774$121
Return visit (30+ min)171$15,581$79
New patient visit (60+ min)69$11,197$162
Critical care, each additional 30 minutes26$7,405$99
Initial hospital care with moderate level of medical decision making at least 75 minutes35$6,224$178
Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days53$2,954$32
Hospital discharge day management, 30 minutes or less33$2,281$65
Programming of multiple lead implantable defibrillator system22$1,661$54
Programming of dual lead implantable defibrillator system23$1,530$53
Programming of dual lead pacemaker system17$635$33
Heart rhythm review and interpretation of continous external ekg over 8-15 days24$622$25
Evaluation of single, dual, or multiple lead implantable defibrillator system17$585$34
Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days16$471$20

2021: 14 services

Original Medicare services billed in 2021
Critical care, first 30-74 minutes49$29,179$197
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes71$24,223$95
Return visit (30+ min)200$19,634$80
Long return visit (40+ min)75$12,237$114
Initial hospital care with moderate level of medical decision making at least 75 minutes53$10,362$185
New patient visit (60+ min)48$8,338$174
Critical care, each additional 30 minutes26$5,806$100
Hospital discharge day management, 30 minutes or less60$4,280$68
Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days51$3,118$32
Programming of dual lead implantable defibrillator system30$1,781$46
Programming of multiple lead implantable defibrillator system21$1,534$51
Heart rhythm review and interpretation of continous external ekg over 8-15 days20$534$25
Programming of dual lead pacemaker system13$504$36
Evaluation of single, dual, or multiple lead implantable defibrillator system12$420$35

2020: 15 services

Original Medicare services billed in 2020
Critical care, first 30-74 minutes45$34,464$202
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes68$22,853$96
Return visit (30+ min)178$15,141$67
Long return visit (40+ min)112$13,748$95
Initial hospital care with moderate level of medical decision making at least 75 minutes49$9,713$183
Critical care, each additional 30 minutes29$9,333$101
New patient visit (60+ min)29$4,562$157
Hospital discharge day management, 30 minutes or less58$4,067$67
Return visit (30+ min)45$3,281$73
Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days51$3,132$34
Initial hospital care with same-day admission and discharge with high level of medical decision making, per day at least 85 minutes11$2,220$202
Programming of multiple lead implantable defibrillator system24$1,628$51
Programming of dual lead implantable defibrillator system23$1,451$48
Review and interpretation of external ekg recording for more than 48 hours up to 21 days23$522$23
Evaluation of single, dual, or multiple lead implantable defibrillator system12$467$36

2019: 13 services

Original Medicare services billed in 2019
Long return visit (40+ min)160$21,639$98
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes62$18,933$94
Critical care, first 30-74 minutes21$14,988$197
Return visit (30+ min)149$11,956$67
Initial hospital care with moderate level of medical decision making at least 75 minutes54$10,278$184
New patient visit (60+ min)63$8,964$142
Hospital discharge day management, 30 minutes or less56$3,782$68
Programming of dual lead implantable defibrillator system40$3,273$50
Critical care, each additional 30 minutes16$3,077$99
Programming of multiple lead implantable defibrillator system36$3,008$52
Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days38$2,375$40
New patient visit (45+ min)17$1,749$103
Programming of dual lead pacemaker system17$675$32

2018: 15 services

Original Medicare services billed in 2018
Critical care, first 30-74 minutes41$25,999$194
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes78$23,661$93
Long return visit (40+ min)125$19,223$94
Return visit (30+ min)133$10,998$63
Initial hospital care with moderate level of medical decision making at least 75 minutes57$10,915$182
New patient visit (60+ min)41$6,171$151
Critical care, each additional 30 minutes22$5,003$98
Hospital discharge day management, 30 minutes or less67$4,881$67
Programming of dual lead implantable defibrillator system30$2,639$52
Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days31$2,413$48
New patient visit (45+ min)18$2,002$111
Programming of multiple lead implantable defibrillator system28$1,781$46
Programming of dual lead pacemaker system14$542$34
Evaluation of single, dual, or multiple lead implantable defibrillator system11$408$31
Review and interpretation of external ekg recording for more than 48 hours up to 21 days11$270$25

2017: 15 services

Original Medicare services billed in 2017
Critical care, first 30-74 minutes43$33,107$196
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes64$22,435$93
Long return visit (40+ min)108$15,621$95
Return visit (30+ min)152$12,901$66
Critical care, each additional 30 minutes26$8,559$98
Initial hospital care with moderate level of medical decision making at least 75 minutes39$7,717$179
New patient visit (60+ min)46$6,670$145
Hospital discharge day management, 30 minutes or less54$3,776$66
New patient visit (45+ min)26$2,888$111
Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days36$2,828$52
Programming of dual lead implantable defibrillator system33$2,477$52
Programming of multiple lead implantable defibrillator system17$1,607$55
Programming of dual lead pacemaker system15$698$33
Review and interpretation of external ekg recording for more than 48 hours up to 21 days19$514$24
Evaluation of single, dual, or multiple lead implantable defibrillator system12$418$35

2016: 14 services

Original Medicare services billed in 2016
Critical care, first 30-74 minutes47$32,557$194
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes86$30,146$92
Long return visit (40+ min)101$14,574$96
Return visit (30+ min)120$10,393$66
Initial hospital care with moderate level of medical decision making at least 75 minutes46$9,374$180
Critical care, each additional 30 minutes23$5,301$98
New patient visit (60+ min)31$4,592$148
Hospital discharge day management, 30 minutes or less62$4,076$66
New patient visit (45+ min)34$3,922$115
Programming of dual lead implantable defibrillator system27$1,744$48
Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days15$1,167$51
Programming of multiple lead implantable defibrillator system18$1,135$57
Programming of dual lead pacemaker system12$488$33
Review and interpretation of external ekg recording for more than 48 hours up to 21 days11$265$24

2015: 13 services

Original Medicare services billed in 2015
Critical care, first 30-74 minutes44$22,704$196
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes71$21,470$91
Long return visit (40+ min)78$12,288$95
Return visit (30+ min)121$9,599$62
Critical care, each additional 30 minutes18$7,863$98
Initial hospital care with moderate level of medical decision making at least 75 minutes35$6,337$181
New patient visit (60+ min)28$4,186$149
Hospital discharge day management, 30 minutes or less57$3,755$66
New patient visit (45+ min)31$3,364$109
Programming of multiple lead implantable defibrillator system21$1,643$53
Programming of dual lead implantable defibrillator system21$1,500$50
Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days19$1,458$54
Programming of dual lead pacemaker system14$829$35

2014: 14 services

Original Medicare services billed in 2014
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes87$32,769$92
Critical care, first 30-74 minutes39$21,697$195
Return visit (30+ min)141$11,994$62
Initial hospital care with moderate level of medical decision making at least 75 minutes65$11,962$179
Long return visit (40+ min)75$11,107$96
Critical care, each additional 30 minutes18$7,823$98
Hospital discharge day management, 30 minutes or less66$4,584$65
New patient visit (60+ min)24$3,590$150
New patient visit (45+ min)28$3,104$111
Programming of dual lead implantable defibrillator system22$2,064$49
Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days21$1,656$52
Programming of multiple lead implantable defibrillator system19$1,168$45
Evaluation of single, dual, or multiple lead implantable defibrillator system14$741$41
Programming of dual lead pacemaker system11$452$27

2013: 16 services

Original Medicare services billed in 2013
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes58$21,291$90
Critical care, first 30-74 minutes34$20,046$191
Return visit (30+ min)146$13,763$63
Long return visit (40+ min)71$7,740$88
Initial hospital care with moderate level of medical decision making at least 75 minutes35$6,472$175
Critical care, each additional 30 minutes17$5,161$96
New patient visit (60+ min)24$3,491$145
Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days21$2,769$53
New patient visit (45+ min)22$2,481$113
Hospital discharge day management, 30 minutes or less35$2,301$64
Evaluation of single, dual, or multiple lead implantable defibrillator system26$1,128$38
Programming of dual lead implantable defibrillator system17$1,097$48
Programming of multiple lead implantable defibrillator system13$868$51
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only110$851$7
Review and interpretation of external ekg recording for more than 48 hours up to 21 days12$257$21
Evaluation of single, dual, multiple lead or leadless pacemaker system11$220$18

Medicaid work

$867 in 2024

Medicaid paid $867 for 32 billed services this clinician did in 2024, up to 12 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES32$867
Medicaid work by year
202432112$867
202312112$306
2022130213$5,967
2021193114$5,886
202039212$2,168
201977113$2,246
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Hospital inpatient or observation discharge day management; 30 minutes or less on the date of the encounter12$306

2022

Largest Medicaid services in 2022
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES117$5,599
Hospital inpatient or observation discharge day management; 30 minutes or less on the date of the encounter13$368

2021

Largest Medicaid services in 2021
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES193$5,886

2020

Largest Medicaid services in 2020
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES27$1,982
Return visit (30+ min)12$186

2019

Largest Medicaid services in 2019
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES77$2,246

Drugs they prescribed that Part D paid

$17,921,531

Pharmacies billed $17,921,531 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 3,519) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.

1,886 generic and fewer than 11 brand-name prescriptions · $17,921,531 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Vyndamax621$14,562,044$23,449
Vyndaqel95$2,145,241$22,581
Jardiance339$464,787$1,371
Eliquis250$341,777$1,367
Entresto169$262,583$1,554
See all 29 drugs
Every Part D drug this clinician prescribed
Vyndamax621$14,562,044$23,449
Vyndaqel95$2,145,241$22,581
Jardiance339$464,787$1,371
Eliquis250$341,777$1,367
Entresto169$262,583$1,554
Farxiga56$61,333$1,095
Xarelto34$35,726$1,051
Eplerenone74$9,744$132
Spironolactone313$3,405$11
Metoprolol183$3,148$17
Carvedilol249$2,873$12
Methotrexate42$2,786$66
Ezetimibe40$2,345$59
Bumetanide36$2,035$57
Furosemide249$1,813$7
Atorvastatin120$1,742$15
Rosuvastatin70$1,141$16
Torsemide17$729$43
Amlodipine Besylate98$658$7
Losartan94$647$7
Levothyroxine27$491$18
Potassium Chloride13$421$32
Hydralazine18$331$18
Clopidogrel29$327$11
Digoxin19$309$16
Amiodarone19$279$15
Hydrochlorothiazide27$233$9
Isosorbide Mononitrate Er14$226$16
Lisinopril50$143$3

Year by year

Part D prescribing by year
20243,5193260% (0)None$17,921,531
20233,3563080% (0)42%$13,300,432
20223,2263070% (0)None$10,462,468
20212,7862760% (0)None$8,630,309
20202,9472960% (0)None$7,885,020
20192,7243110% (0)None$2,618,839
20182,7482780% (0)None$290,754
20172,296259None23%$197,483
20162,136236NoneNone$155,514
20152,2672220% (0)None$127,959
20142,484221NoneNone$109,014
20132,079185NoneNone$92,916

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 34 drugs

Part D drugs prescribed in 2023
Vyndamax500$10,983,005$21,966
Vyndaqel53$1,216,452$22,952
Eliquis271$342,003$1,262
Entresto215$319,694$1,487
Jardiance241$291,880$1,211
Farxiga35$43,550$1,244
Xarelto33$39,819$1,207
Eplerenone72$10,927$152
Bumetanide44$5,643$128
Spironolactone333$4,871$15
Carvedilol270$4,426$16
Metoprolol148$3,266$22
Rosuvastatin60$3,020$50
Atorvastatin138$2,899$21
Methotrexate35$2,661$76
Furosemide251$2,657$11
Ezetimibe26$1,560$60
Losartan91$1,041$11
Amlodipine Besylate88$862$10
Amiodarone23$851$37
Hydralazine21$634$30
Digoxin21$524$25
Torsemide22$515$23
Lisinopril70$474$7
Isosorbide Mononitrate Er15$415$28
Potassium Chloride14$395$28
Levothyroxine26$383$15
Clopidogrel20$354$18
Hydrochlorothiazide35$342$10
Metoprolol13$262$20
Donepezil12$243$20
Pravastatin11$167$15
Diltiazem 24hr Er (Xr)12$151$13
Nitroglycerin15$116$8

2022: 33 drugs

Part D drugs prescribed in 2022
Vyndamax403$8,458,597$20,989
Vyndaqel54$1,150,212$21,300
Entresto261$299,766$1,149
Eliquis272$269,605$991
Jardiance140$135,088$965
Xarelto35$44,572$1,273
Farxiga39$30,699$787
Eplerenone77$20,344$264
Spironolactone332$4,174$13
Bumetanide31$4,081$132
Rosuvastatin43$3,737$87
Carvedilol235$2,948$13
Methotrexate43$2,711$63
Furosemide248$2,695$11
Metoprolol135$2,620$19
Amiodarone25$2,576$103
Midodrine17$2,138$126
Atorvastatin127$2,083$16
Ezetimibe31$1,932$62
Digoxin35$1,085$31
Losartan108$1,038$10
Amlodipine Besylate103$831$8
Isosorbide Mononitrate Er30$815$27
Potassium Chloride19$666$35
Hydralazine18$577$32
Torsemide25$557$22
Lisinopril74$479$6
Levothyroxine21$444$21
Hydrochlorothiazide29$385$13
Pantoprazole13$232$18
Donepezil12$216$18
Clopidogrel14$215$15
Metoprolol18$157$9

2021: 31 drugs

Part D drugs prescribed in 2021
Vyndamax333$6,681,328$20,064
Vyndaqel68$1,364,352$20,064
Eliquis242$226,478$936
Entresto150$173,422$1,156
Jardiance63$55,880$887
Xarelto46$49,267$1,071
Farxiga20$14,076$704
Eplerenone58$12,831$221
Spironolactone311$4,490$14
Methotrexate34$3,711$109
Carvedilol241$3,524$15
Metoprolol147$3,052$21
Bumetanide35$2,920$83
Furosemide240$2,411$10
Midodrine24$2,111$88
Atorvastatin132$1,979$15
Rosuvastatin39$1,678$43
Digoxin39$1,330$34
Amiodarone19$1,292$68
Losartan112$1,131$10
Lisinopril66$912$14
Ezetimibe16$749$47
Torsemide11$704$64
Amlodipine Besylate64$612$10
Levothyroxine18$558$31
Hydralazine20$454$23
Isosorbide Mononitrate Er20$410$20
Hydrochlorothiazide27$313$12
Potassium Chloride19$274$14
Metoprolol14$166$12
Prednisone12$99$8

2020: 27 drugs

Part D drugs prescribed in 2020
Vyndamax217$4,313,393$19,877
Vyndaqel153$3,136,304$20,499
Eliquis216$176,412$817
Entresto143$139,963$979
Xarelto50$39,782$796
Eplerenone52$9,266$178
Spironolactone328$4,138$13
Metoprolol141$3,647$26
Bumetanide38$3,014$79
Amiodarone39$2,923$75
Carvedilol297$2,907$10
Furosemide302$2,791$9
Midodrine35$2,613$75
Methotrexate34$2,598$76
Atorvastatin149$2,313$16
Rosuvastatin24$1,866$78
Digoxin45$1,600$36
Losartan126$1,492$12
Isosorbide Mononitrate Er36$993$28
Lisinopril68$619$9
Hydralazine40$597$15
Levothyroxine27$587$22
Amlodipine Besylate68$479$7
Metoprolol39$457$12
Potassium Chloride18$451$25
Hydrochlorothiazide38$415$11
Pantoprazole20$294$15

2019: 34 drugs

Part D drugs prescribed in 2019
Vyndaqel100$2,022,403$20,224
Vyndamax11$213,735$19,430
Eliquis178$128,836$724
Entresto150$102,645$684
Xarelto65$34,329$528
Eplerenone97$29,073$300
Bumetanide59$7,261$123
Amiodarone52$4,160$80
Metoprolol136$3,922$29
Carvedilol283$3,794$13
Spironolactone283$3,497$12
Furosemide238$2,658$11
Midodrine20$2,472$124
Methotrexate23$2,450$107
Atorvastatin117$2,001$17
Digoxin48$1,746$36
Losartan133$1,331$10
Hydralazine46$1,331$29
Isosorbide Mononitrate Er38$1,201$32
Rosuvastatin18$1,182$66
Torsemide32$1,160$36
Lisinopril64$1,048$16
Diflunisal14$968$69
Potassium Chloride25$968$39
Digox13$685$53
Amlodipine Besylate57$583$10
Metoprolol36$499$14
Hydrochlorothiazide44$423$10
Levothyroxine24$380$16
Tamsulosin18$348$19
Gabapentin13$278$21
Warfarin12$172$14
Clopidogrel11$104$9
Omeprazole12$83$7

2018: 34 drugs

Part D drugs prescribed in 2018
Eliquis143$94,747$663
Entresto117$70,556$603
Xarelto78$40,916$525
Eplerenone79$16,123$204
Carvedilol344$3,868$11
Spironolactone346$3,857$11
Amiodarone57$3,494$61
Bumetanide51$3,365$66
Atorvastatin136$2,682$20
Metoprolol104$2,547$24
Furosemide282$2,446$9
Digoxin55$2,260$41
Ezetimibe11$1,908$173
Diflunisal21$1,870$89
Isosorbide Mononitrate Er54$1,770$33
Midodrine17$1,493$88
Valsartan23$1,376$60
Digox21$1,218$58
Losartan138$1,202$9
Hydralazine60$1,155$19
Potassium Chloride24$1,002$42
Lisinopril66$989$15
Amlodipine Besylate82$773$9
Hydrochlorothiazide65$543$8
Rosuvastatin12$412$34
Tamsulosin12$351$29
Metoprolol29$350$12
Pantoprazole19$316$17
Warfarin14$287$20
Allopurinol11$247$22
Clopidogrel21$245$12
Simvastatin12$130$11
Gabapentin11$128$12
Omeprazole14$75$5

2017: 34 drugs

Part D drugs prescribed in 2017
Xarelto66$38,589$585
Eliquis72$36,780$511
Entresto52$31,204$600
Eplerenone58$17,316$299
Brilinta15$4,986$332
Spironolactone342$3,702$11
Bumetanide33$3,497$106
Amiodarone36$3,184$88
Midodrine37$2,826$76
Carvedilol276$2,253$8
Metoprolol70$2,158$31
Digoxin37$2,086$56
Furosemide288$1,800$6
Valsartan18$1,445$80
Atorvastatin72$1,352$19
Diflunisal13$1,289$99
Losartan122$1,080$9
Isosorbide Mononitrate Er42$1,073$26
Digox17$1,020$60
Hydralazine42$771$18
Amlodipine Besylate79$709$9
Torsemide21$563$27
Levothyroxine25$542$22
Lisinopril72$506$7
Clopidogrel31$439$14
Warfarin18$361$20
Simvastatin27$325$12
Metoprolol29$325$11
Hydrochlorothiazide32$323$10
Pravastatin15$285$19
Diltiazem 24hr Er12$277$23
Potassium Chloride15$241$16
Pantoprazole14$162$12
Niacor12$123$10

2016: 37 drugs

Part D drugs prescribed in 2016
Xarelto66$37,326$566
Eliquis35$15,945$456
Eplerenone45$10,733$239
Pradaxa20$9,502$475
Entresto18$8,005$445
Zetia15$6,058$404
Spironolactone271$3,130$12
Amiodarone42$3,073$73
Colchicine14$3,021$216
Metoprolol78$2,780$36
Valsartan32$2,647$83
Carvedilol222$2,228$10
Furosemide269$1,640$6
Bumetanide26$1,620$62
Digoxin43$1,613$38
Potassium Chloride28$1,099$39
Atorvastatin46$1,065$23
Hydralazine59$958$16
Isosorbide Mononitrate Er49$914$19
Midodrine21$797$38
Losartan91$743$8
Lisinopril62$664$11
Digox15$615$41
Levothyroxine26$571$22
Diltiazem 24hr Cd14$540$39
Amlodipine Besylate61$469$8
Torsemide13$412$32
Warfarin26$377$15
Methotrexate12$375$31
Metoprolol38$340$9
Clopidogrel34$339$10
Simvastatin33$289$9
Benazepril18$158$9
Niacor12$125$10
Pantoprazole14$121$9
Venlafaxine Hcl Er11$108$10
Hydrochlorothiazide19$89$5

2015: 36 drugs

Part D drugs prescribed in 2015
Xarelto82$35,203$429
Pradaxa27$10,720$397
Eliquis19$8,252$434
Eplerenone39$7,818$200
Crestor23$6,011$261
Midodrine22$4,558$207
Colchicine14$3,255$233
Spironolactone287$2,520$9
Metoprolol80$2,392$30
Amiodarone70$2,271$32
Carvedilol259$2,219$9
Furosemide257$1,703$7
Digoxin35$1,596$46
Methotrexate18$1,575$87
Atorvastatin61$1,554$25
Valsartan25$1,511$60
Hydralazine82$1,416$17
Isosorbide Mononitrate Er75$1,161$15
Potassium Chloride41$992$24
Levothyroxine38$767$20
Losartan90$556$6
Diltiazem 24hr Cd14$492$35
Lisinopril76$474$6
Digox14$458$33
Clopidogrel36$393$11
Metoprolol51$357$7
Warfarin44$322$7
Simvastatin33$313$9
Amlodipine Besylate39$309$8
Tamsulosin13$296$23
Ramipril14$222$16
Hydrochlorothiazide29$212$7
Prednisone12$176$15
Allopurinol13$152$12
Metformin28$133$5
Escitalopram12$100$8

2014: 42 drugs

Part D drugs prescribed in 2014
Xarelto68$26,919$396
Crestor27$8,615$319
Pradaxa24$7,145$298
Eliquis20$5,932$297
Diovan18$4,201$233
Methotrexate33$3,694$112
Metoprolol94$3,415$36
Amiodarone57$3,313$58
Colcrys12$2,916$243
Eplerenone26$2,859$110
Carvedilol263$2,824$11
Spironolactone233$2,323$10
Hydralazine111$2,272$20
Digox35$1,910$55
Furosemide264$1,606$6
Isosorbide Mononitrate Er108$1,530$14
Atorvastatin64$1,401$22
Digoxin24$1,266$53
Midodrine17$1,264$74
Losartan85$1,008$12
Lisinopril125$797$6
Amlodipine Besylate78$728$9
Potassium Chloride22$634$29
Tamsulosin21$563$27
Levothyroxine36$559$16
Prednisone27$491$18
Clopidogrel22$422$19
Simvastatin42$409$10
Warfarin43$384$9
Ramipril12$357$30
Metformin35$347$10
Metoprolol49$336$7
Diltiazem 24hr Cd12$263$22
Hydrochlorothiazide38$263$7
Enalapril Maleate11$178$16
Benazepril19$163$9
Omeprazole16$157$10
Zolpidem12$156$13
Allopurinol16$108$7
Gabapentin13$108$8
Sulfamethoxazole-Trimethoprim16$71$4
Folic Acid13$37$3

2013: 35 drugs

Part D drugs prescribed in 2013
Xarelto55$15,421$280
Diovan62$12,675$204
Pradaxa36$10,450$290
Eplerenone32$5,943$186
Crestor14$4,756$340
Carvedilol262$3,608$14
Metoprolol95$2,991$31
Spironolactone188$2,472$13
Colcrys12$2,432$203
Hydralazine91$2,392$26
Atorvastatin45$1,835$41
Isosorbide Mononitrate Er89$1,424$16
Furosemide191$1,214$6
Amlodipine Besylate106$989$9
Losartan56$901$16
Lisinopril118$788$7
Clopidogrel28$697$25
Amiodarone43$663$15
Simvastatin63$613$10
Isosorbide Dinitrate12$581$48
Digox53$518$10
Hydrochlorothiazide50$473$9
Midodrine14$413$29
Enalapril Maleate30$378$13
Metoprolol39$333$9
Warfarin20$315$16
Pantoprazole12$303$25
Ramipril16$266$17
Tamsulosin19$262$14
Benazepril28$218$8
Levothyroxine13$141$11
Pravastatin12$133$11
Allopurinol16$119$7
Digoxin11$112$10
Metformin13$90$7

Money from drug and device companies

$39,578 in 2025

Industry payments by year
2025519$37,322$39,578
2024437$48,924$64,859
2023619$33,062$47,173
2022523$23,571$59,581
202146$14,793$14,793
202022$6,000$6,000
2019419$16,945$18,606

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
PfizerVyndaqel$13,849
6 payments
  • Consulting · 2025-11-24 · $2,800
  • Paid to speak or teach for Vyndaqel · 2025-11-10 · $186
  • Consulting for Vyndaqel · 2025-11-10 · $5,600
  • Consulting for Vyndaqel · 2025-11-10 · $2,800
  • Paid to speak or teach for Vyndaqel · 2025-08-25 · $1,063
  • Consulting for Vyndaqel · 2025-04-17 · $1,400
Alnylam PharmaceuticalsOnpattro$11,207
7 payments
  • Meals · 2025-09-26 · $132
  • Travel for Amvuttra · 2025-09-26 · $734
  • Travel for Amvuttra · 2025-09-26 · $621
  • Travel for Amvuttra · 2025-09-26 · $308
  • Paid to speak or teach · 2025-03-29 · $4,125
  • Consulting · 2025-03-13 · $2,820
  • Consulting for Onpattro · 2025-01-16 · $2,468
BridgeBio PharmaAttruby$10,175
3 payments
  • Meals for Attruby · 2025-12-16 · $146
  • Meals for Attruby · 2025-10-01 · $264
  • Consulting for Attruby · 2025-05-27 · $9,765
AstraZeneca Pharmaceuticals LPWainua$2,737
2 payments
  • Consulting for Wainua · 2025-10-01 · $2,685
  • Meals for Wainua · 2025-09-28 · $52
AstraZeneca ABNone$1,611
1 payment
  • Consulting · 2025-07-10 · $1,611
See all 19 published payments
Every published payment
BridgeBio PharmaMeals · 2025-12-16Attruby$146
PfizerConsulting · 2025-11-24None$2,800
PfizerPaid to speak or teach · 2025-11-10Vyndaqel$186
PfizerConsulting · 2025-11-10Vyndaqel$5,600
PfizerConsulting · 2025-11-10Vyndaqel$2,800
AstraZeneca Pharmaceuticals LPConsulting · 2025-10-01Wainua$2,685
BridgeBio PharmaMeals · 2025-10-01Attruby$264
AstraZeneca Pharmaceuticals LPMeals · 2025-09-28Wainua$52
Alnylam PharmaceuticalsMeals · 2025-09-26None$132
Alnylam PharmaceuticalsTravel · 2025-09-26Amvuttra$734
Alnylam PharmaceuticalsTravel · 2025-09-26Amvuttra$621
Alnylam PharmaceuticalsTravel · 2025-09-26Amvuttra$308
PfizerPaid to speak or teach · 2025-08-25Vyndaqel$1,063
AstraZeneca ABConsulting · 2025-07-10None$1,611
BridgeBio PharmaConsulting · 2025-05-27Attruby$9,765
PfizerConsulting · 2025-04-17Vyndaqel$1,400
Alnylam PharmaceuticalsPaid to speak or teach · 2025-03-29None$4,125
Alnylam PharmaceuticalsConsulting · 2025-03-13None$2,820
Alnylam PharmaceuticalsConsulting · 2025-01-16Onpattro$2,468
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $64,859

Payments by company in 2024
PfizerVyndaqel$45,311
18 payments
  • Paid to speak or teach for Vyndamax · 2024-12-31 · $1,400
  • Paid to speak or teach for Vyndamax · 2024-11-13 · $5,600
  • Consulting for Vyndamax · 2024-11-08 · $4,200
  • Travel for Vyndaqel · 2024-11-04 · $1,924
  • Travel · 2024-10-31 · $118
  • Meals for Vyndamax · 2024-10-18 · $151
  • Travel for Vyndamax · 2024-10-18 · $1,123
  • Travel for Vyndamax · 2024-10-18 · $369
  • Consulting for Vyndamax · 2024-10-17 · $2,800
  • Consulting for Vyndaqel · 2024-10-10 · $6,300
  • Travel for Vyndaqel · 2024-09-27 · $9,106
  • Meals for Vyndaqel · 2024-09-27 · $102
  • Meals for Vyndaqel · 2024-08-29 · $52
  • Paid to speak or teach for Vyndaqel · 2024-08-19 · $3,150
  • Paid to speak or teach for Vyndaqel · 2024-08-13 · $4,812
  • Travel for Vyndaqel · 2024-06-04 · $405
  • Travel for Vyndaqel · 2024-05-30 · $400
  • Consulting for Vyndaqel · 2024-05-28 · $3,300
Alnylam PharmaceuticalsAmvuttra$10,117
16 payments
  • Travel · 2024-10-31 · $118
  • Travel · 2024-09-04 · $641
  • Travel · 2024-09-04 · $358
  • Travel · 2024-08-27 · $145
  • Travel · 2024-08-27 · $140
  • Consulting · 2024-04-19 · $4,935
  • Travel · 2024-04-19 · $36
  • Travel · 2024-04-19 · $36
  • Travel · 2024-04-19 · $21
  • Travel · 2024-04-19 · $298
  • Meals · 2024-04-19 · $138
  • Meals · 2024-04-05 · $40
  • Meals · 2024-04-05 · $36
  • Meals · 2024-04-05 · $55
  • Consulting · 2024-03-01 · $2,996
  • Meals for Amvuttra · 2024-02-29 · $125
Alexion PharmaceuticalsNone$7,820
2 payments
  • Consulting · 2024-11-05 · $5,520
  • Consulting · 2024-10-18 · $2,300
AstraZeneca Pharmaceuticals LPNone$1,611
1 payment
  • Consulting · 2024-10-25 · $1,611

2023: $47,173

Payments by company in 2023
Novo Nordisk ASNone$21,141
6 payments
  • Travel · 2023-03-13 · $34
  • Meals · 2023-03-13 · $280
  • Travel · 2023-03-13 · $501
  • Travel · 2023-03-13 · $734
  • Travel · 2023-03-13 · $5,835
  • Consulting · 2023-03-13 · $13,756
Alnylam PharmaceuticalsOnpattro$12,851
4 payments
  • Meals for Onpattro · 2023-11-12 · $21
  • Consulting · 2023-11-02 · $9,071
  • Travel · 2023-10-19 · $2,836
  • Consulting · 2023-02-23 · $923
AstraZeneca Pharmaceuticals LPWainua$4,961
3 payments
  • Meals for Wainua · 2023-10-07 · $128
  • Consulting · 2023-08-10 · $1,074
  • Consulting · 2023-03-23 · $3,759
PfizerVyndaqel$4,316
4 payments
  • Travel for Vyndaqel · 2023-04-26 · $1,174
  • Paid to speak or teach for Vyndaqel · 2023-03-06 · $799
  • Travel for Vyndaqel · 2023-03-06 · $393
  • Travel for Vyndaqel · 2023-03-06 · $1,951
Alexion PharmaceuticalsNone$3,680
1 payment
  • Consulting · 2023-12-12 · $3,680
Pfizer Corporation Hong KongVyndamax$224
1 payment
  • Meals for Vyndamax · 2023-06-10 · $224

2022: $59,581

Payments by company in 2022
PfizerVyndaqel$25,545
10 payments
  • Travel for Vyndaqel · 2022-09-27 · $430
  • Travel for Vyndaqel · 2022-09-20 · $1,142
  • Travel for Vyndaqel · 2022-09-14 · $713
  • Travel for Vyndaqel · 2022-09-08 · $1,082
  • Paid to speak or teach for Vyndaqel · 2022-09-08 · $661
  • Travel for Vyndaqel · 2022-09-08 · $8,976
  • Paid to speak or teach for Vyndaqel · 2022-08-29 · $1,016
  • Travel for Vyndaqel · 2022-08-29 · $568
  • Travel for Vyndaqel · 2022-08-29 · $10,714
  • Travel for Vyndaqel · 2022-08-29 · $244
Novo Nordisk ASNone$24,373
5 payments
  • Travel · 2022-04-01 · $11,153
  • Consulting · 2022-04-01 · $12,563
  • Meals · 2022-04-01 · $121
  • Travel · 2022-04-01 · $153
  • Travel · 2022-04-01 · $383
Alnylam PharmaceuticalsNone$4,613
3 payments
  • Consulting · 2022-07-29 · $615
  • Consulting · 2022-05-27 · $1,538
  • Consulting · 2022-01-07 · $2,460
Alexion PharmaceuticalsNone$3,645
1 payment
  • Consulting · 2022-07-07 · $3,645
AstraZeneca Pharmaceuticals LPLokelma$1,405
4 payments
  • Meals · 2022-11-06 · $81
  • Consulting · 2022-10-23 · $1,074
  • Meals · 2022-10-01 · $120
  • Meals for Lokelma · 2022-09-24 · $130

2021: $14,793

Payments by company in 2021
Akcea TherapeuticsNone$5,300
2 payments
  • Consulting · 2021-09-21 · $2,650
  • Consulting · 2021-02-02 · $2,650
Regeneron PharmaceuticalsNone$5,265
2 payments
  • Consulting · 2021-08-13 · $585
  • Consulting · 2021-07-23 · $4,680
Alnylam PharmaceuticalsNone$2,460
1 payment
  • Consulting · 2021-04-29 · $2,460
Janssen Scientific AffairsDarzalex$1,768
1 payment
  • Consulting for Darzalex · 2021-10-06 · $1,768

2020: $6,000

Payments by company in 2020
PfizerVyndaqel$3,500
1 payment
  • Consulting for Vyndaqel · 2020-12-21 · $3,500
Pfizer InternationalVyndaqel$2,500
1 payment
  • Paid to speak or teach for Vyndaqel · 2020-11-06 · $2,500

2019: $18,606

Payments by company in 2019
Alnylam PharmaceuticalsOnpattro$11,330
11 payments
  • Meals for Onpattro · 2019-12-02 · $95
  • Travel for Onpattro · 2019-12-02 · $81
  • Consulting for Onpattro · 2019-12-02 · $1,750
  • Travel for Onpattro · 2019-10-30 · $528
  • Consulting for Onpattro · 2019-09-27 · $4,655
  • Travel for Onpattro · 2019-09-20 · $139
  • Meals for Onpattro · 2019-09-20 · $26
  • Meals for Onpattro · 2019-09-20 · $83
  • Consulting for Onpattro · 2019-05-15 · $3,510
  • Travel for Onpattro · 2019-05-15 · $365
  • Meals for Onpattro · 2019-03-16 · $98
PfizerVyndaqel$7,030
6 payments
  • Paid to speak or teach for Vyndaqel · 2019-12-30 · $1,400
  • Paid to speak or teach for Vyndaqel · 2019-12-02 · $330
  • Paid to speak or teach for Vyndaqel · 2019-11-27 · $330
  • Paid to speak or teach for Vyndaqel · 2019-10-29 · $330
  • Paid to speak or teach for Vyndaqel · 2019-09-16 · $940
  • Paid to speak or teach for Vyndaqel · 2019-01-22 · $3,700
Medtronic VascularReveal Linq$153
1 payment
  • Meals for Reveal Linq · 2019-09-21 · $153
Akcea TherapeuticsTegsedi$93
1 payment
  • Meals for Tegsedi · 2019-09-15 · $93

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Alnylam Pharmaceuticals Inc. · Helios-B: A Study To Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy · 2024Their institution$850,188
Alnylam Pharmaceuticals Inc. · Helios-B: A Study To Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy · 2021Their institution$615,954
Alnylam Pharmaceuticals Inc. · Helios-B: A Study To Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy · 2025Their institution$411,471
Janssen Research & Development, LLC · A Phase 1 Study of Daratumumab Sc for Reduction of Circulating Antibodies in Patients With High All Sensitization Awaiting Heart Transplantation · 2023Their institution$346,238
Ionis Pharmaceuticals, Inc. · A Phase 3 Global Doubleblind Randomized Placebocontrolled Study To Evaluate the Efficacy and Safety of Ion682884 in Patients With Transthyretinmediated Amyloid Cardiomyopathy Attrcm · 2025Their institution$304,267
Alnylam Pharmaceuticals Inc. · Helios-B: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (Attr Amyloidosis With Cardiomyopathy) · 2023Their institution$166,833
Alnylam Pharmaceuticals Inc. · Helios-B: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (Attr Amyloidosis With Cardiomyopathy) · 2022Their institution$158,902
PFIZER INC. · A Phase 3 Multicenter Randomized Doubleblind Extension Study To Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine Pf06291826 20 Mg Or 80 Mg in Subjects Diagnosed With Transthyretin Cardiomyopathy Ttrcm · 2019Their institution$158,664
PFIZER INC. · A Phase 3 Multicenter Randomized Doubleblind Extension Study To Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine Pf06291826 20 Mg Or 80 Mg in Subjects Diagnosed With Transthyretin Cardiomyopathy Ttrcm · 2020Their institution$147,664
Alnylam Pharmaceuticals Inc. · Helios-B: A Study To Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy · 2022Their institution$133,542
Alnylam Pharmaceuticals Inc. · Helios-B: A Study To Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy · 2020Their institution$121,225
PFIZER INC. · A Phase 3 Multicenter Openlabel Study To Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine Pf0629182683 20 Mg Or 80 Mg Or Tafamidis Pf0629182600 61 Mg in Subjects Diagnosed With Transthyretin Cardiomyopathy Attrcm · 2022Their institution$120,144
Alnylam Pharmaceuticals Inc. · An Open-Label Extension Study To Assess the Safety and Efficacy of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (Attr Amyloidosis With Cardiomyopathy) · 2025Their institution$97,623
Ionis Pharmaceuticals, Inc. · An Openlabel Extension Study To Assess the Longterm Safety of Eplontersen Ion682884 in Patients With Transthyretinmediated Amyloid Cardiomyopathy Attrcm · 2025Their institution$86,165
Janssen Research & Development, LLC · A Phase 1 Study of Daratumumab Sc for Reduction of Circulating Antibodies in Patients With High All Sensitization Awaiting Heart Transplantation · 2024Their institution$36,455
Janssen Research & Development, LLC · A Phase 1 Study of Daratumumab Sc for Reduction of Circulating Antibodies in Patients With High All Sensitization Awaiting Heart Transplantation · 2021Their institution$27,202
Alexion Pharmaceuticals, Inc. · A Phase 3,Radomized,Double-Blind,Placebo-Controlled,Multicenter Study To Evaluate the Efficacy and Safety of Amyloid Depleter Alxn2220 in Adult Participants Wiith Transthyretin Amyloid Cardiomyopathy Attr Cm · 2025Their institution$18,302
PFIZER INC. · A Phase 3 Multicenter Openlabel Study To Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine Pf0629182683 20 Mg Or 80 Mg Or Tafamidis Pf0629182600 61 Mg in Subjects Diagnosed With Transthyretin Cardiomyopathy Attrcm · 2023Their institution$11,897
PFIZER INC. · Tafamidis Meglumine Clinical Publication Program · 2025This clinician$7,480
PFIZER INC. · Tafamidis Clinical Publication Program · 2020This clinician$6,890
Genentech, Inc. · T Dm1 High Risk Ebc Pts With Residual Inv Disease · 2019This clinician$6,800
PFIZER INC. · Tafamidis Clinical Publication Program · 2022This clinician$6,030
PFIZER INC. · Tafamidis Clinical Publication Program · 2021This clinician$5,740
PFIZER INC. · Tafamidis Meglumine Clinical Publication Program · 2023This clinician$5,090
PFIZER INC. · Vyndaqel Clinical Publication Program · 2024This clinician$4,470
Janssen Research & Development, LLC · A Phase 1 Study of Daratumumab Sc for Reduction of Circulating Antibodies in Patients With High All Sensitization Awaiting Heart Transplantation · 2025Their institution$4,310
PFIZER INC. · A Phase 3 Multicenter Openlabel Study To Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine Pf0629182683 20 Mg Or 80 Mg Or Tafamidis Pf0629182600 61 Mg in Subjects Diagnosed With Transthyretin Cardiomyopathy Attrcm · 2024Their institution$4,000
PFIZER INC. · A Phase 3 Multicenter Openlabel Study To Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine Pf0629182683 20 Mg Or 80 Mg Or Tafamidis Pf0629182600 61 Mg in Subjects Diagnosed With Transthyretin Cardiomyopathy Attrcm · 2025Their institution$4,000
PFIZER INC. · Vyndamax Clinical Publication Program · 2023This clinician$3,200
Janssen Research & Development, LLC · A Phase 1 Study of Daratumumab Sc for Reduction of Circulating Antibodies in Patients With High All Sensitization Awaiting Heart Transplantation · 2022Their institution$2,491
PFIZER INC. · Tafamidis Meglumine Clinical Publication Program · 2022This clinician$1,560
PFIZER INC. · Tafamidis Meglumine Clinical Publication Program · 2024This clinician$1,440

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1285779389
Licence
CA A76510California A76510: Current · expires 2027-04-30
Trained
University of Chicago, Pritzker School of Medicine, 2000
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207RA0001X (207RA0001X); Internal medicine (207R00000X); Cardiology (207RC0000X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2007-02-20
NPI last updated
2024-04-26
NPI record certified
2024-04-26

This is when the NPI record was last certified, not a medical board exam.